Abstract
ObjectiveTo evaluate the diagnostic performance of [68Ga]Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA-PET) in the early detection of metastases in patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to compare it to CT/MRI alone and to assess its impact on further therapeutic decisions.Material and methodsWe retrospectively assessed 117 consecutive hormone-naïve BCR patients who had 68Ga-PSMA 11 PET/CT (n = 46) or PET/MRI (n = 71) between May 2014 and January 2017. BCR was defined as two PSA rises above 0.2 ng/ml. Two dedicated uro-oncological imaging experts (radiology/nuclear medicine) reviewed separately all images. All results were presented in a blinded sequential fashion to a multidisciplinary tumorboard in order to assess the influence of PSMA-PET imaging on decision-making.ResultsThe median time from RP to BCR was 36 months (IQR 16–72). Overall, 69 (59%) patients received postoperative radiotherapy. Median PSA level at the time of imaging was 1.04 ng/ml (IQR 0.58–1.87). PSMA-positive lesions were detected in 100 (85.5%) patients. Detection rates were 65% for a PSA value of 0.2 to <0.5 ng/ml, 85.7% for 0.5 to <1, 85.7% for 1 to <2 and 100% for ≥2. PSMA-positive lesions could be confirmed by either histology (16%), PSA decrease in metastasis-directed radiotherapy (45%) or additional information in diffusion-weighted imaging when PET/MRI was performed (18%) in 79% of patients. PSMA-PET detected lesions in 67 patients (57.3%) who had no suspicious correlates according to the RECIST 1.1 criteria on MRI or CT. PSMA-PET changed therapeutic decisions in 74.6% of these 67 patients (p < 0.001), with 86% of them being considered for metastases-directed therapies.ConclusionsWe confirm the high performance of PSMA-PET imaging for the detection of disease recurrence sites in patients with BCR after RP, even at relatively low PSA levels. Moreover, it adds significant information to standard CT/MRI, changing treatment strategies in a significant number of patients.
Highlights
Introduction medianprostate-specific antigen (PSA) levels and contributes a major impact on the clinical decision-making process
PSMAHBED-CC conjugate 11 (PSMA)-positive lesions could be confirmed by either histology (16%), PSA decrease in metastasis-directed radiotherapy (45%) or additional information in diffusion-weighted imaging when positron emission tomography (PET)/MRI was performed (18%) in 79% of patients
PSMA-PET changed therapeutic decisions in 74.6% of these 67 patients (p < 0.001), with 86% of them being considered for metastases-directed therapies
Summary
Introduction medianPSA levels and contributes a major impact on the clinical decision-making process. The aim of this study was to evaluate the diagnostic performance of PSMA-PET in the early detection of metastases in patients with BCR at lower PSA levels after RP for clinically non-metastatic PC and to assess its impact on therapeutic decision-making compared to standard imaging with CT/MRI. Despite attempted local therapy with curative intent, up to 40% [2] of the patients experience disease recurrence. Most of these patients have prostate-specific antigen (PSA)-only recurrence without any clinical evidence of metastases [3]. Salvage RT is most effective when PSA levels are below 0.5 ng/ml [8,9,10] At this threshold, the actual imaging techniques are limited in their sensitivity to differentiate local versus distant recurrence. Contrastenhanced computerized tomography (CT) and bone scan (BS), the current standard diagnostic tests for staging of PC, have, inadequate sensitivity for the detection of PC in PSA ranges below 10 ng/ml [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
